---

VDRL Positive in an HIV-Positive Patient: Clinical Importance

---

1. Epidemiological Significance

• Genital ulcers from syphilis disrupt mucosal barriers, increasing HIV acquisition and transmission risk
• Both share common transmission routes (unprotected sex, especially MSM)
• Active syphilis increases HIV viral shedding in genital secretions

---

2. Atypical Serological Behavior

---

3. Risk of Neurosyphilis

• CNS invasion by T. pallidum occurs early in 25-33% of all syphilis infections (HIV-infected or not)
• In HIV-infected persons, CNS infection is more often progressive, making early detection essential
• HIV co-infected patients have an 11-fold higher risk of neurosyphilis if RPR titer ≥1:32 (compared to 6-fold in HIV-uninfected)
• HIV-infected patients with CD4+ count ≤350/μL are at particularly high risk

Indications for CSF Examination (Lumbar Puncture)

• Neurological signs or symptoms (meningitis, stroke-like deficits, dementia)
• Ophthalmic symptoms (uveitis, iritis, visual loss)
• Otologic symptoms (hearing loss, tinnitus)
• Cranial nerve dysfunction
• RPR titer ≥1:32
• CD4+ count ≤350/μL
• Treatment failure

---

4. Altered Clinical Presentation

• Multiple chancres (rather than the classic single ulcer) in primary syphilis
• More aggressive, florid secondary syphilis
• Atypical rashes and presentations
• Rapid progression through stages
• Earlier and more frequent symptomatic neurosyphilis (meningitis, meningovascular syphilis, optic/auditory nerve involvement)

---

5. Treatment Considerations

• Penicillin G benzathine does NOT achieve treponemicidal CSF levels - viable T. pallidum have been isolated from CSF of HIV-infected patients even after standard therapy
• Multiple cases of neurologic relapse after standard therapy have been reported in HIV-co-infected patients
• If neurosyphilis is confirmed (abnormal CSF): treat with aqueous crystalline penicillin G IV (18-24 MU/day for 10-14 days)
• If the HIV-positive patient has penicillin allergy with confirmed late latent or unknown-duration syphilis, desensitization and treatment with penicillin is required (doxycycline is insufficient in this context)
• Azithromycin single-dose therapy is not reliable in HIV co-infection (treatment failures reported)

---

6. Follow-Up and Monitoring

---

7. Dual Testing Rule

---

Summary

---

Histopathology Report Analysis - Prostate Carcinoma

---

Report Summary (Extracted Findings)

---

Gleason Score Interpretation

• Pattern 3 (primary, 80%): Well-formed discrete glands - the least aggressive pattern
• Pattern 4 (secondary, 20%): Poorly formed, fused, or cribriform glands - intermediate aggressiveness

---

NCCN Risk Stratification

Determining Favorable vs. Unfavorable Intermediate

Per NCCN: Unfavorable intermediate = Grade Group 2 with PSA 10-20 OR clinical stage T2b-c OR >50% positive biopsy cores.

---

Special Concern: Cribriform Pattern 4

1. Higher biochemical recurrence and disease-specific mortality compared to non-cribriform Gleason 4
2. The pathology report explicitly notes: "Presence of cribriform pattern 4 tumor warrants a workup for homologous recombination repair gene deficiency" - this means BRCA1/BRCA2 and other HRR gene testing (somatic ± germline) is indicated
3. HRR-deficient tumors are candidates for PARP inhibitor therapy (olaparib, rucaparib) - an FDA-approved pathway for metastatic castration-resistant prostate cancer
4. Cribriform pattern alone, even in a Gleason 3+4 context, upgrades the biological aggressiveness and shifts the risk more toward the unfavorable intermediate category

---

Extent of Carcinoma

---

Recommended Workup Based on Risk Category

1. mpMRI of the prostate - assess extracapsular extension (ECE), seminal vesicle invasion (SVI), and local staging (T2 vs T3)
2. PSMA PET scan - now standard-of-care for Grade Group 2-3 and above for nodal and distant metastasis staging (superior to CT + bone scan)
3. HRR gene panel testing (somatic from biopsy tissue + germline blood test) - indicated due to cribriform pattern 4, as noted by the pathologist
4. Pelvic lymph node assessment - if nomogram predicts >10% probability of nodal involvement
5. Bone imaging - if PSA >10 ng/mL confirmed (bone scan or PSMA PET covers this)

---

Summary

---

EAU Risk Stratification - Chandrakant Patel

EAU Risk Group Framework (2025 Guidelines)

EAU 2025 Risk Groups (Table 4.3)

---

Applying EAU Criteria to This Patient

Two Possible EAU Outcomes Depending on PSA:

---

Key EAU-Specific Points for This Patient

1. Cribriform / Intraductal Carcinoma - EAU Now Recognises This

"Risk stratifications incorporating invasive cribriform and/or intraductal carcinoma (CR/IDC) have shown better performance in predicting post-treatment biochemical recurrence than the three-tier EAU, NCCN and CAPRA models."

2. Active Surveillance Eligibility (EAU 2025)

• Favourable Intermediate (GG2, PSA <10): Active surveillance may be discussed as an option for selected patients per EAU 2025
• Unfavourable Intermediate (GG2, PSA 10-20): Active surveillance is not recommended - definitive treatment (radical prostatectomy or radiotherapy) is indicated
• Given the cribriform pattern 4 and ~70% bilateral tumor burden, this patient is NOT a candidate for active surveillance under EAU guidelines, regardless of PSA

3. EAU Imaging Recommendations Based on Risk

---

Comparison: EAU vs. NCCN for This Patient

Key difference: EAU does not use % positive biopsy cores in its formal criteria, unlike NCCN. Therefore, the 70% bilateral core involvement that pushed this patient to Unfavorable Intermediate under NCCN does not independently change the EAU category - the PSA value is the decisive factor here.

---

Bottom Line - EAU Risk Category

---

Summary in Brief

1. BCR workup & treatment:

• Repeat PSA → calculate doubling time
• PSMA PET/CT (first and best imaging at this PSA level - near 100% detection)
• Based on result: Salvage RT ± short-course ADT (local), or ADT + novel agent (metastatic)

1. Incontinence:

• Must first rule out anastomotic stricture or local tumour recurrence as a cause
• Urethrocystoscopy + urodynamics
• Conservative (PFMT) first; AUS is gold standard but must be deferred until after any planned pelvic radiotherapy

1. Renal impairment (Cr 1.72):

• Rule out ureteric obstruction by lymphadenopathy (renal USS urgently)
• Optimise hypertension management
• Tailor systemic therapy to GFR (prefer darolutamide over other agents; denosumab over zoledronate if bone mets)

---

Which ADT to Prefer with Salvage RT for Local Recurrence?

---

1. The ADT Classes: GnRH Agonist vs. GnRH Antagonist

---

2. The Key Question: Does Class Matter for RT + BCR?

Flare Suppression

Cardiovascular Risk - The PRONOUNCE Trial (RCT, 2021)

• Primary MACE (death/MI/stroke) at 12 months: 5.5% degarelix vs. 4.1% leuprolide (HR 1.28, p=0.53 - no significant difference)
• Trial was underpowered (stopped early, only 545/900 enrolled)
• Conclusion: No statistically proven CV superiority of antagonist over agonist in formal RCT

---

3. Relugolix - The Newer Oral Option (HERO Trial)

• 54% relative reduction in MACE vs. leuprolide (HR 0.46, 95% CI 0.24-0.88) in a post-hoc cardiovascular analysis
• Rapid testosterone suppression within 4 days
• Rapid testosterone recovery (~90 days after stopping) - ideal for short-course ADT alongside RT
• Advantage for this patient: Oral daily administration, rapid recovery aligns perfectly with 6-month short-course ADT alongside RT

---

4. Duration of ADT with Salvage RT

• 4-6 months short-course ADT is reasonable for lower-risk BCR (Gleason ≤7, low PSA, slow doubling time)
• 24 months ADT considered for higher-risk BCR (Gleason 8+, seminal vesicle involvement, rapid doubling time, PSA >0.5 before SRT)
• For this patient with PSA 4.46 and intermediate Gleason (3+4), 6 months is a reasonable starting point

---

5. Specific Recommendation for This Patient

Preferred: Relugolix 120 mg oral daily (after 360 mg loading dose on Day 1)

1. No testosterone flare - safe in hypertensive/CV-risk patient without need for antiandrogen cover
2. Rapid testosterone suppression - synchronises well with the start of RT
3. Rapid testosterone recovery after the 6-month course - important for bone health, quality of life, and metabolic recovery in a 76-year-old
4. HERO trial data suggests superior CV safety vs. GnRH agonists (though PRONOUNCE was inconclusive)
5. Oral - avoids monthly injections, easier in an elderly outpatient
6. CKD-safe: No dose adjustment needed for renal impairment

• Degarelix 240 mg SC (loading) then 80 mg SC monthly - no flare, immediate suppression, acceptable CV profile
• Add bicalutamide 50 mg daily x 4 weeks if using a GnRH agonist (leuprolide/goserelin) to prevent testosterone flare

ADT Monitoring in This Patient

---

Summary Table

---

CT Angiography Analysis & Partial Nephrectomy Feasibility

Patient Details (from imaging)

---

What the CT Angiography Shows

Left Kidney (the critical side)

Right Kidney

• Normal size, shape, morphology - no mass
• Single main renal artery + one accessory inferior polar artery
• No relevant pathology

Aorta

• Normal course, caliber - no aneurysm or significant atherosclerosis
• Normal bifurcation into common iliacs

---

Can Partial Nephrectomy be Done?

Short Answer: YES - Technically feasible, but moderately to highly complex

---

Factors FAVOURING Partial Nephrectomy

---

Factors CHALLENGING or Complicating Partial Nephrectomy

---

RENAL Nephrometry Considerations

• Longer operative time
• Higher estimated blood loss
• Longer warm ischemia time
• Higher complication rate
• Greater risk of positive margins
• Need for experienced surgical centre

---

Surgical Strategy if Partial Nephrectomy is Pursued

Key Steps for Safe Execution

1. Pre-operative 3D vascular mapping - this CT angiogram is the key tool. A 3D reconstruction (which appears to already be done) should be used for precise surgical planning
2. Selective arterial clamping strategy:

• Identify and clamp the superior branch of the main left renal artery (which feeds the mass) selectively
• Leave the accessory lower polar arteries unclamped to maintain lower pole perfusion throughout
• This "selective segmental ischaemia" technique dramatically reduces total nephron ischaemic injury

1. Approach:

• Robotic-assisted partial nephrectomy (RAPN) preferred - superior precision, better 3D visualisation, easier hilar dissection, and easier suturing
• Transperitoneal approach for upper pole tumours gives better access

1. Zero-ischaemia technique - with selective branch clamping and the lower pole's independent supply, true zero-ischaemia to the salvageable parenchyma may be achievable
2. Intraoperative ultrasound - to confirm tumour margins and collecting system involvement
3. Prepare for radical nephrectomy conversion - if haemostasis cannot be achieved or margins are compromised intraoperatively

---

Important Pre-operative Workup Required

---

Alternative if Partial Nephrectomy Deemed Too Risky

---

Summary

• Are you asking whether something in my previous answer is correct or unclear?
• Do you have a specific follow-up question about this patient (Varsha Mahajan, 58F, left renal mass)?
• Are you asking about a different aspect - e.g., staging, biopsy, surgical approach, anaesthetic risk, or something else?

---

Is Partial Nephrectomy Possible in This Patient?

Patient: Varsha Mahajan, Female, 58 years

---

The Single Most Important Vascular Finding

The lower pole of the left kidney is supplied by 2-3 independent accessory renal arteries arising directly from the infrarenal aorta - completely separate from the main renal artery branch feeding the upper pole tumour.

• The upper pole tumour has its own distinct blood supply (superior branch of main left renal artery)
• The normal lower pole parenchyma has its own independent blood supply from the aorta
• These two territories are vascularly separable

---

Direct Answer: YES - Partial Nephrectomy IS Possible

Why YES:

---

However - It Is HIGH Complexity Surgery

---

Recommended Surgical Approach

1. Pre-operative 3D vascular reconstruction (already available from this CT angio)
2. Selective clamping of the superior branch of the main left renal artery only (tumour supply)
3. Accessory lower polar arteries left unclamped throughout - preserving lower pole perfusion
4. Intraoperative ultrasound for real-time margin assessment
5. Consent for conversion to radical nephrectomy if haemostasis or margins cannot be secured

---

If Partial Nephrectomy Fails Intraoperatively

---

Bottom Line

---

Follow-Up Management: Metastatic Ca Prostate on Enzalutamide 160 mg x 2 Years

First - Establish Clinical Status at Follow-Up

---

Step 1: Mandatory Follow-Up Investigations

A. Disease Status Assessment

B. Toxicity / Monitoring for Enzalutamide Side Effects (2-year exposure)

C. Molecular Profiling (if not already done - critical at this point)

After 2 years on enzalutamide, this is the time to check actionable mutations if not previously done.

---

Step 2: Three Possible Clinical Scenarios and Management

Scenario A: PSA Falling/Stable, No New Lesions, No Symptoms = RESPONDING

• Continue current regimen
• Maintain castrate testosterone
• Continue bone protection: Denosumab 120 mg SC every 4 weeks (or zoledronic acid 4 mg IV every 4 weeks if eGFR permits) + calcium + vitamin D supplementation
• Screen and manage ADT side effects (metabolic, bone, cardiovascular)
• Reassess in 3 months

---

Scenario B: PSA Rising But No Radiological Progression = BIOCHEMICAL PROGRESSION

• Is testosterone truly castrate? (If not - optimise ADT first)
• Is PSA rise sustained? (2 confirmatory PSA values, 3 weeks apart)
• Rule out "PSA flare" phenomenon

• Do NOT switch to another androgen receptor signalling inhibitor (ARSI) - cross-resistance is well established

  "If patients received a newer-generation hormonal therapy, another similar agent should not be used. Instead, another agent with a different mechanism of action, such as docetaxel, should be considered." - Goldman-Cecil Medicine

• Perform PSMA PET/CT to localise disease
• Initiate next-line therapy based on molecular status (see below)

---

Scenario C: PSA Rising + Radiological Progression = CASTRATION-RESISTANT DISEASE (mCRPC)

---

Step 3: Next-Line Treatment Options After Enzalutamide Failure

Priority 1: Docetaxel Chemotherapy (if not previously used)

• 75 mg/m² IV every 3 weeks + prednisolone 5 mg BD
• First choice after ARSI failure if no prior taxane exposure
• Improves OS by ~2-3 months in mCRPC
• Consider if: PS 0-2, adequate bone marrow and renal/hepatic function

Priority 2: Cabazitaxel (if docetaxel previously given)

• 25 mg/m² IV every 3 weeks + prednisolone
• For docetaxel-refractory mCRPC
• CARD trial showed superiority over abiraterone/enzalutamide switch in ARSI-pretreated patients

Priority 3: 177Lu-PSMA-617 (Lutetium PSMA Radioligand Therapy)

• Indication: PSMA-positive mCRPC (confirmed on PSMA PET/CT) who have had prior ARSI and taxane
• VISION trial (2021): Lu-PSMA-617 + standard of care vs. standard of care alone - significantly improved rPFS (8.7 vs 3.4 months) and OS (15.3 vs 11.3 months)
• Now FDA-approved (2022) - requires positive PSMA PET/CT
• "177Lu-PSMA-617 targets PSMA, which is highly expressed in prostate cancer, as demonstrated by a positive PSMA PET/CT scan" - Goldman-Cecil Medicine
• Ideally needs: PSMA PET/CT confirming PSMA-positive disease, prior docetaxel, prior ARSI (both boxes ticked here)

Priority 4: PARP Inhibitors (if HRR mutation present)

• "If molecular profiling reveals deleterious germline or somatic HRR gene, treatment with PARP inhibitors (olaparib, rucaparib) is useful post-abiraterone or enzalutamide" - Goldman-Cecil Medicine
• This is why HRR gene testing NOW is mandatory at the 2-year enzalutamide follow-up

Priority 5: Radium-223 Dichloride (if symptomatic bone mets, NO visceral mets)

• 6 monthly IV injections
• Improves OS ~3.6 months, reduces symptomatic skeletal events
• Only for bone-dominant disease with no visceral metastases
• Cannot be combined with docetaxel (increased fracture risk)

Priority 6: Pembrolizumab (if MSI-H / dMMR / TMB-high)

• ~5% of mCRPC patients have MSI-H
• Requires tumour molecular profiling
• FDA-approved for any MSI-H solid tumour

Priority 7: Sipuleucel-T (if asymptomatic/minimally symptomatic, no visceral mets)

• Autologous dendritic cell immunotherapy
• Modest OS benefit (~4 months) in asymptomatic mCRPC
• Not suitable for rapidly progressing/symptomatic disease

---

Decision Framework at This Follow-Up Visit

Is PSA rising or falling?
    │
    ├── FALLING / STABLE → Continue enzalutamide + ADT
    │   Monitor bone density, metabolic, CVS, cognitive
    │
    └── RISING (confirmed x2)
        │
        ├── Check testosterone - castrate?
        │   No → Optimise ADT first
        │
        └── Yes, castrate + rising PSA
            │
            ├── Do PSMA PET/CT → localise disease
            ├── Do AR-V7 testing
            ├── Do HRR gene panel
            │
            ├── HRR mutation? → Olaparib/Rucaparib
            ├── MSI-H/dMMR? → Pembrolizumab
            ├── PSMA+ (post-taxane)? → 177Lu-PSMA-617
            ├── No prior docetaxel? → DOCETAXEL (first choice)
            ├── Post-docetaxel? → CABAZITAXEL
            └── Bone mets only, no visceral → RADIUM-223

---

Bone Health - Mandatory at 2-Year Review

---

Summary Table

---

Tebipenem (UTEBZI) - Complete Drug Information

Historic significance: Tebipenem pivoxil (brand name UTEBZI, developed by GSK/Spero Therapeutics) is the world's first oral carbapenem approved for use in adults - a landmark in antibiotic development. FDA approval granted 2026.

---

1. Basic Classification

---

2. Mechanism of Action

• Binds PBPs 1a, 1b, 2, 3, 4, and 5/6 in E. coli and Klebsiella pneumoniae
• Preferential binding to PBP 2 - disrupts peptidoglycan cross-linking → osmotic instability → bacterial lysis
• Bactericidal; time-dependent killing
• PK-PD index: fAUC24:MIC ratio predicts antibacterial efficacy (AUC-driven, not Cmax-driven)

---

3. Antimicrobial Spectrum

Active Against (Gram-negative focus):

Resistance Mechanisms:

• Carbapenemases (KPC, NDM, OXA - these inactivate tebipenem)
• Altered PBPs
• Efflux pump overexpression
• Outer membrane protein loss (porin loss)
• Cross-resistance with other carbapenems
• Spontaneous resistance mutation frequency: <1.4×10⁻⁹ to 5.54×10⁻⁵ at 4× MIC (very low)

Not Reliable Against:

• Pseudomonas aeruginosa (similar to ertapenem - insufficient activity)
• Gram-positive organisms (limited role)
• Anaerobes - limited data
• Carbapenem-resistant organisms (CRE, NDM producers)

---

4. FDA-Approved Indication

Complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis (AP) in adults caused by susceptible Enterobacterales:

• E. coli, K. pneumoniae, Proteus mirabilis

• Non-inferior to IV ertapenem for clinical and microbiological cure
• Enables oral-only treatment or IV-to-oral step-down for MDR uropathogens
• AEs: tebipenem 25.7% vs. ertapenem 25.6% (comparable)
• C. difficile: 0 cases with tebipenem vs. 3 with ertapenem

---

5. Dosing

Standard Adult Dose (eGFR 60-150 mL/min):

⚠️ Note: The FDA label specifies q6h dosing. The ADAPT-PO trial used q8h - both regimens have been studied. The approved regimen is q6h.

Renal Dose Adjustment (from FDA label):

Administration:

• Can be taken with or without food
• Swallow tablets whole
• Maximum treatment duration: 7-10 days (do not extend beyond recommended duration)

---

6. Pharmacokinetics

---

7. Contraindications

1. Hypersensitivity to tebipenem/UTEBZI or any other beta-lactam antibacterial (penicillins, cephalosporins, carbapenems)
2. Primary or secondary carnitine deficiency or inborn errors of metabolism that cause clinically significant carnitine deficiency

---

8. Warnings and Precautions

---

9. Drug Interactions

---

10. Adverse Effects

Common (≥3% in clinical trials):

• Diarrhoea (most common)
• Headache
• Nausea (mild)
• All were mild-moderate, non-serious in ADAPT-PO and PIVOT-PO trials

Serious (class-effect, less common):

• Seizures (especially with high doses + renal impairment)
• Anaphylaxis / severe hypersensitivity
• C. difficile colitis
• Carnitine depletion (with prolonged use)

---

11. Special Populations

---

12. Clinical Position & Key Advantages

---

13. What It Does NOT Cover (Important Limitations)

---

Summary Card

---

Urodynamic Pressure-Flow Study Analysis

---

Report Data Extraction

Filling Phase Results

Sensation Results

Bladder Compliance (Linear Regression)

Normal: >20 ml/cmH₂O | Moderately impaired: 10-20 | Severely impaired: <10

Voiding Phase Results

---

Nomogram Analysis

ICS Detrusor-Flow Plot (Abrams-Griffiths / ICS Nomogram)

• Pdet at Qmax = 60 cmH₂O
• Qmax = 1.6 ml/s (≈ 2 ml/s on plot)
• Plot position: Upper left quadrant = OBSTRUCTED zone
• A/G (Abrams-Griffiths) number = 56

A/G Number = Pdet@Qmax − 2 × Qmax = 60 − (2 × 2) = 56

• 40 = Obstructed

• 20-40 = Equivocal
• <20 = Unobstructed

Siroky Nomogram

• Average flow rate: 1 ml/s → Below -3 SD (far below normal range)
• Qmax: 2 ml/s → Below -3 SD
• Both markers fall in the severely obstructed / markedly abnormal zone

Liverpool Nomogram

• Voided volume 13 ml
• Average flow rate 1 ml/s → Falls in the lowest percentile - severely abnormal for volume voided

---

Marker Overview Interpretation

• Pdet remains relatively flat during filling (no spontaneous detrusor overactivity spikes)
• Urgency noted at 405 ml (near MCC)
• At MCC: Pdet = 33 cmH₂O - acceptable but upper limit

---

Summary of Urodynamic Findings

---

Urodynamic Diagnosis

Primary Diagnosis:

Bladder Outlet Obstruction (BOO) - Severe

Contributing / Secondary Finding:

Detrusor Underactivity / Impaired Detrusor Contractility

• The Pdet at Qmax of 60 cmH₂O confirms obstruction (A/G = 56, ICS = Obstructed)
• However, the fact that only 13 ml was voided despite a Pdet of 60 with 394 ml PVR suggests the detrusor contraction, while present, is unable to sustain adequate voiding - this represents a component of detrusor underactivity (DUA) on a background of BOO
• The prolonged hesitancy (108 seconds) and short flow time (23 s out of 171 s voiding time) suggest the patient is straining/Valsalva voiding with intermittent minimal flow
• The voided volume of 13 ml is below the minimum 50 ml threshold for a valid pressure-flow study - results must be interpreted with this caveat

"The results are only valid under normative conditions: minimum voided volume of 50-100 ml" - Campbell-Walsh-Wein Urology

---

Clinical Correlation

---

Clinical Implications and Recommended Management

Immediate Concerns:

1. PVR of 394 ml out of 407 ml capacity = near-complete urinary retention - risk of:

• Upper tract damage (hydronephrosis, renal impairment)
• Recurrent UTI
• Bladder decompensation

1. Mildly reduced compliance (18.9 ml/cmH₂O) - if this deteriorates further (<10), upper tract at risk

Management Strategy:

---

Key Numbers at a Glance